Eton Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and nine months ended September 30, 2023. Eton develops, acquires, and commercializes medicines for rare diseases. Its commercial products included ALKINDI SPRINKLE, Carglumic Acid, and Betaine Anhydrous; it also reported three late-stage candidates. On October 11, 2023, after quarter-end, Eton acquired an FDA-approved ANDA for Nitisinone Capsules.
Financial performance and position
| Metric | Three months ended Sept. 30 | Nine months ended Sept. 30 |
|---|---|---|
| Net revenue, 2023 | $7.028 million | $24.329 million |
| Net revenue, 2022 | $3.219 million | $12.753 million |
| Gross profit, 2023 | $4.403 million | $17.431 million |
| Gross margin, 2023 | 62.6% | 71.6% |
| Operating income (loss), 2023 | ($0.548) million | $0.801 million |
| Net income (loss), 2023 | ($0.579) million | $1.320 million |
| Net income (loss) per share, diluted | ($0.02) | $0.05 |
- At September 30, cash and cash equivalents were $22.070 million, total assets $31.526 million, and working capital approximately $16.8 million. Current assets were $27.157 million and current liabilities $10.393 million.
- Debt carrying value was $5.737 million: $1.540 million current and $4.197 million long-term. The SWK loan is secured, bears interest at Term SOFR plus 8.26% with a 5.0% floor, and is scheduled to mature in November 2024. Cash exceeded reported debt by about $16.3 million.
- For the first nine months, operating cash flow was $6.428 million, investing cash flow was zero, financing cash flow was negative $0.663 million, and cash increased $5.765 million. Cash interest paid was $0.638 million.
Changes versus the prior comparable periods
- Q3 revenue rose 118% year over year, primarily from higher ALKINDI SPRINKLE and Carglumic Acid sales. Nine-month revenue rose 91%; product sales and royalties increased to $18.829 million from $7.753 million.
- Nine-month licensing revenue was $5.5 million versus $5.0 million. The 2023 amount included $5.5 million from selling royalty interests to Azurity; the 2022 amount included $5.0 million in licensing revenue from the Dr. Reddy’s transaction.
- Gross margin was broadly flat in Q3 versus the prior year (62.6% versus 62.7%), while nine-month margin increased to 71.6% from 62.4%. Mix and licensing revenue contributed to the nine-month change.
- Nine-month operating results improved from a $9.322 million operating loss to $0.801 million operating income, and net results improved from a $9.933 million loss to $1.320 million income. The 2023 nine-month results included an $0.800 million acquisition-auction breakup fee.
- Cash from operations increased to $6.428 million from $1.981 million, mainly reflecting higher sales and gross profit. Research and development expense declined to $2.275 million from $3.052 million; general and administrative expense was approximately flat at $14.355 million versus $14.228 million.
Outlook, commentary, and risks
- Management stated that cash on hand and revenue from approved products are expected to fund operating expenses and capital needs for at least 12 months from the filing date. This depends on sales and spending assumptions; the company cautioned that capital could be depleted sooner and additional financing may not be available on acceptable terms.
- Management said sales growth was driven by ALKINDI SPRINKLE and Carglumic Acid. G&A increased modestly, including sales-force expansion costs, partly offset by lower third-party sales commissions.
- Revenue and receivables are concentrated: AnovoRx accounted for 73% of nine-month 2023 revenue and 98% of net receivables at September 30. Eton also relies on a small number of third-party suppliers for key products and development activities.
- Other material considerations include execution and regulatory risks for development candidates, estimates for rebates, chargebacks and other revenue reductions, and debt covenants that limit dividends and other distributions. The filing reported no pending or threatened litigation expected to materially affect operations and no off-balance-sheet transactions.
Important facts for investors to verify
- Whether the sharp product-sales growth and customer concentration persist, particularly given AnovoRx’s share of revenue and receivables.
- Whether the company achieves its stated 12-month liquidity outlook and manages working capital, debt service, and the November 2024 loan maturity.
- Commercial progress, regulatory milestones, and required investment for ZENEO, ET-400, ET-600, and the post-quarter Nitisinone acquisition.
- The sustainability of positive nine-month earnings and cash flow, including the effects of the Azurity royalty sale and the one-time breakup fee.